Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs,a Natural Host of VSV

Abstract

Vesicular stomatitis virus (VSV) is a negative-stranded RNA virus that naturally causes disease in livestock including horses, cattle and pigs. The two main identified VSV serotypes are New Jersey (VSNJV) and Indiana (VSIV). VSV is a rapidly replicating, potently immunogenic virus that has been engineered to develop novel oncolytic therapies for cancer treatment. Swine are a natural host for VSV and provide a relevant and well-established model, amenable to biological sampling to monitor virus shedding and neutralizing antibodies. Previous reports have documented the pathogenicity and transmissibility of wild-type isolates and recombinant strains of VSIV and VSNJV using the swine model. Oncolytic VSV engineered to express interferon-beta (IFNβ) and the sodium iodide symporter (NIS), VSV-IFNβ-NIS, has been shown to be a potent new therapeutic agent inducing rapid and durable tumor remission following systemic therapy in preclinical mouse models. VSV-IFNβ-NIS is currently undergoing clinical evaluation for the treatment of advanced cancer in human and canine patients. To support clinical studies and comprehensively assess the risk of transmission to susceptible species, we tested the pathogenicity and transmissibility of oncolytic VSV-IFNβ-NIS using the swine model. Following previously established protocols to evaluate VSV pathogenicity, intradermal inoculation with 10⁷ TCID₅₀ VSV-IFNβ-NIS caused no observable symptoms in pigs. There was no detectable shedding of infectious virus in VSV-IFNβ-NIS in biological excreta of inoculated pigs or exposed naive pigs kept in direct contact throughout the experiment. VSV-IFNβ-NIS inoculated pigs became seropositive for VSV antibodies, while contact pigs displayed no symptoms of VSV infection, and importantly did not seroconvert. These data indicate that oncolytic VSV is both nonpathogenic and not transmissible in pigs, a natural host. These findings support further clinical development of oncolytic VSV-IFNβ-NIS as a safe therapeutic for human and canine cancer.

Get full access to this article

View all access options for this article.

References

USDA Animal and Plant Health Inspection Service, Veterinary Services. 2015 Vesicular Stomatitis Virus (VSV) Situation Report—March 4, 2016. Riverdale, MD: United States Department of Agriculture, Animal and Plant Health Inspection Service, 2016.

Stallknecht

, Greer

, Murphy

, Mead

, Howerth

. Effect of strain and serotype of vesicular stomatitis virus on viral shedding, vesicular lesion development, and contact transmission in pigs. Am J Vet Res, 2004; 65:1233–1239.

Martinez

, Barrera

, Rodriguez

, Wertz

. Recombinant vesicular stomatitis (Indiana) virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host. Vaccine, 2004; 22:4035–4043.

Martinez

, Rodriguez

, Jimenez

, Pauszek

, Wertz

. Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J Virol, 2003; 77:8039–8047.

Lawson

, Stillman

, Whitt

, Rose

. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A, 1995; 92:4477–4481.

Balachandran

, Barber

. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life, 2000; 50:135–138.

Lichty

, Power

, Stojdl

, Bell

. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med, 2004; 10:210–216.

Stojdl

, Lichty

, tenOever

, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell, 2003; 4:263–275.

Henao-Restrepo

, Longini

, Egger

, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet, 2015; 386:857–866.

10.

Naik

, Russell

. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther, 2009; 9:1163–1176.

11.

Naik

, Nace

, Barber

, Russell

. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther, 2012; 19:443–450.

12.

Goel

, Carlson

, Classic

, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood, 2007; 110:2342–2350.

13.

Obuchi

, Fernandez

, Barber

. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol, 2003; 77:8843–8856.

14.

U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products—Guidance for Industry. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration, 2015.

15.

Bailey

, Kirk

, Naik

, et al. Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. PLoS One, 2013; 8:e73759.

16.

Naik

, Nace

, Federspiel

, Barber

, Peng

, Russell

. Curative one-shot systemic virotherapy in murine myeloma. Leukemia, 2012; 26:1870–1878.

17.

Dingli

, Russell

, Morris

, 3rd. In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem, 2003; 90:1079–1086.

18.

Zhang

, Steele

, Jenks

, et al. Safety studies in tumor and non-tumor-bearing mice in support of clinical trials using oncolytic VSV-IFNbeta-NIS. Hum Gene Ther Clin Dev, 2016; 27:111–122.

19.

Zhang

, Steele

, Jenks

, et al. Robust oncolytic virotherapy induces tumor lysis syndrome and associated toxicities in the MPC-11 plasmacytoma model. Mol Ther, 2016; 24:2109–2117.

20.

LeBlanc

, Naik

, Galyon

, et al. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. Hum Gene Ther Clin Dev, 2013; 24:174–181.

21.

Gresser

, Bandu

, Brouty-boye

, Tovey

. Pronounced antiviral activity of human interferon on bovine and porcine cells. Nature, 1974; 251:543–545.

22.

Miller

, Suksanpaisan

, Naik

, et al. Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy. Mol Ther Oncolytics, 2014; 1:14005.

23.

Wilson

, Letchworth

, Jimenez

, et al. Field evaluation of a multiplex real-time reverse transcription polymerase chain reaction assay for detection of Vesicular stomatitis virus. J Vet Diagn Invest, 2009; 21:179–186.

24.

Arzt

, Pacheco

, Rodriguez

. The early pathogenesis of foot-and-mouth disease in cattle after aerosol inoculation. Identification of the nasopharynx as the primary site of infection. Vet Pathol, 2010; 47:1048–1063.

25.

Pacheco

, Mason

. Evaluation of infectivity and transmission of different Asian foot-and-mouth disease viruses in swine. J Vet Sci, 2010; 11:133–142.

26.

Bukreyev

, Skiadopoulos

, Murphy

, Collins

. Nonsegmented negative-strand viruses as vaccine vectors. J Virol, 2006; 80:10293–10306.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB